Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice

H Cain; I R Macpherson; M Beresford; S E Pinder; J Pong; J M Dixon

doi:10.1016/j.clon.2017.06.003

Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice

Clin Oncol (R Coll Radiol). 2017 Oct;29(10):642-652. doi: 10.1016/j.clon.2017.06.003. Epub 2017 Jun 29.

Authors

H Cain¹, I R Macpherson², M Beresford³, S E Pinder⁴, J Pong⁵, J M Dixon⁶

Affiliations

¹ Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: [email protected].
² Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
³ Department of Clinical Oncology, The Royal United Hospital, Bath, UK.
⁴ Division of Cancer Studies, King's College London, Guy's Hospital, London, UK.
⁵ Roche Products Ltd, Welwyn Garden City, UK.
⁶ Edinburgh Breast Unit, Western General Hospital, NHS Lothian, Edinburgh, UK.

PMID: 28669449
DOI: 10.1016/j.clon.2017.06.003

Abstract

Neoadjuvant treatment offers a number of benefits for patients with early breast cancer, and is an important option for consideration by multidisciplinary teams. Despite literature showing its efficacy, the use of neoadjuvant therapy varies widely. Here we discuss the clinical evidence supporting the use of neoadjuvant therapy in early stage breast cancer, including patient selection, monitoring response, surgery and radiotherapy considerations, with the aim of assisting multidisciplinary teams to determine patient suitability for neoadjuvant treatment.

Keywords: Breast cancer; chemotherapy; endocrine therapy; multidisciplinary; neoadjuvant treatment; patient management.

Publication types

Review

MeSH terms

Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Female
Humans
Neoadjuvant Therapy / methods*